###begin article-title 0
Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 358 363 <span type="species:ncbi:9606">women</span>
Cancer therapies directed at specific molecular targets in signaling pathways of cancer cells, such as tamoxifen, aromatase inhibitors and trastuzumab, have proven useful for treatment of advanced breast cancers. However, increased risk of endometrial cancer with long-term tamoxifen administration and of bone fracture due to osteoporosis in postmenopausal women undergoing aromatase inhibitor therapy are recognized side effects. These side effects as well as drug resistance make it necessary to search for novel molecular targets for drugs on the basis of well-characterized mechanisms of action.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 75 116 75 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">maternal embryonic leucine-zipper kinase </italic>
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK</italic>
###xml 221 226 221 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 309 314 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 446 447 446 447 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 773 774 773 774 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
Using accurate genome-wide expression profiles of breast cancers, we found maternal embryonic leucine-zipper kinase (MELK) to be significantly overexpressed in the great majority of breast cancer cells. To assess whether MELK has a role in mammary carcinogenesis, we knocked down the expression of endogenous MELK in breast cancer cell lines using mammalian vector-based RNA interference. Furthermore, we identified a long isoform of Bcl-G (Bcl-GL), a pro-apoptotic member of the Bcl-2 family, as a possible substrate for MELK by pull-down assay with recombinant wild-type and kinase-dead MELK. Finally, we performed TUNEL assays and FACS analysis, measuring proportions of apoptotic cells, to investigate whether MELK is involved in the apoptosis cascade through the Bcl-GL-related pathway.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 447 449 447 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 528 530 528 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 570 578 570 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 674 675 674 675 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 364 369 <span type="species:ncbi:9606">human</span>
Northern blot analyses on multiple human tissues and cancer cell lines demonstrated that MELK was overexpressed at a significantly high level in a great majority of breast cancers and cell lines, but was not expressed in normal vital organs (heart, liver, lung and kidney). Suppression of MELK expression by small interfering RNA significantly inhibited growth of human breast cancer cells. We also found that MELK physically interacted with Bcl-GL through its amino-terminal region. Immunocomplex kinase assay showed that Bcl-GL was specifically phosphorylated by MELK in vitro. TUNEL assays and FACS analysis revealed that overexpression of wild-type MELK suppressed Bcl-GL-induced apoptosis, while that of D150A-MELK did not.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 154 155 154 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
Our findings suggest that the kinase activity of MELK is likely to affect mammary carcinogenesis through inhibition of the pro-apoptotic function of Bcl-GL. The kinase activity of MELK could be a promising molecular target for development of therapy for patients with breast cancers.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 675 676 675 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 677 678 677 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 62 67 <span type="species:ncbi:9606">women</span>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 594 602 <span type="species:ncbi:9606">patients</span>
Breast cancer is one of the leading causes of cancer death in women worldwide. According to a 2002 estimate, more than 1,100,000 patients were newly diagnosed with breast cancer, and approximately 410,000 patients died of the disease [1]. Recent improvements in detecting breast cancer at an early stage through mammographic screening have contributed to a decrease in breast cancer-associated mortality. Mastectomy is among the first options for treatment of localized breast cancer. Despite surgical removal of primary tumors, however, relapse at local or distant sites occurs in a subset of patients, probably due to undetectable micrometastases at the time of diagnosis [2,3].
###end p 11
###begin p 12
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 463 464 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 858 859 858 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 860 861 860 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 397 402 <span type="species:ncbi:9606">human</span>
###xml 469 477 <span type="species:ncbi:9606">Patients</span>
###xml 784 789 <span type="species:ncbi:9606">women</span>
Cancer therapies directed at specific molecular targets in signaling pathways of cancer cells, such as tamoxifen, aromatase inhibitors and trastuzumab (Herceptin), have been proven to be useful for treatment of advanced breast cancer [4]. Tamoxifen and aromatase inhibitors suppress the estrogen-related signaling pathway and trastuzumab is the first approved monoclonal antibody for blocking the human epidermal growth factor 2 (HER-2/ErbB-2) signaling pathway [4,5]. Patients with tumors that express estrogen or HER-2 receptors can benefit from either of these therapies and are expected to have a better quality of life and prognosis. However, increased risk of endometrial cancer with long-term tamoxifen administration and of bone fracture due to osteoporosis in postmenopausal women undergoing aromatase inhibitor therapy are recognized side effects [6,7]. Due to the emergence of these side effects and also because of drug resistance, it is necessary to search for novel molecular targets for drugs on the basis of well-characterized mechanisms of action.
###end p 12
###begin p 13
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 398 439 398 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">maternal embryonic leucine zipper kinase </italic>
###xml 440 444 440 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK</italic>
###xml 351 356 <span type="species:ncbi:9606">human</span>
Toward the goal of identifying good molecular targets for drug development, we analyzed the detailed expression profiles of 81 breast tumors, representing 23,040 genes, using a combination of laser-microbeam microdissection and cDNA microarray analysis [8]. After comparing the expression profiles of these breast cancers with those of various normal human tissues [9], we focused on a gene termed maternal embryonic leucine zipper kinase (MELK) that was significantly overexpressed in the great majority of breast cancer cases examined.
###end p 13
###begin p 14
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 297 298 297 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 499 500 499 500 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
In this study, we report evidence indicating that MELK functions as a cancer-specific protein kinase, and that down-regulation of MELK results in growth suppression of breast cancer cells. In addition, we demonstrate that MELK physically interacts and phosphorylates a long isoform of Bcl-G (Bcl-GL), a pro-apoptotic member of the Bcl-2 family. Our findings suggest that the kinase activity of MELK is likely to affect mammary carcinogenesis through inhibition of the pro-apoptotic function of Bcl-GL. We propose that MELK kinase activity could be a promising molecular target for the treatment of breast cancer.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
Cancer cell lines and clinical samples
###end title 16
###begin p 17
###xml 1421 1422 1415 1416 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1499 1500 1487 1488 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 204 208 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 317 322 <span type="species:ncbi:9606">Human</span>
###xml 1220 1226 <span type="species:ncbi:9913">bovine</span>
Human breast cancer cell lines HBL100, HCC1937, MCF-7, MDA-MB-231, MDA-MB-435S, SKBR3, T47D, YMB1, BSY-1 and BT-20, human cervical adenocarcinoma cell line, HeLa, and monkey kidney cells transformed with SV40 T-antigen, COS7 cells, were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). Human mammary epithelial cells (HMECs) were purchased from Cambrex Bio Science Walkersville, Inc. (Walkersville, MD, USA). HBC4 and HBC5 cells lines were kind gifts from Dr Yamori of the Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research. All cells were cultured under their respective depositor's recommendations: RPMI-1640 (Sigma-Aldrich, St Louis, MO, USA) for HBC4, HBC5, HCC1937, SKBR3, T47D, YMB1 and BSY-1 (with 2 mM L-glutamine); Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) for HBL100, BT-20 and COS7; EMEM (Sigma-Aldrich) with 0.1 mM essential amino acid (Roche, Basel, Switzerland), 1 mM sodium pyruvate (Roche), 0.01 mg/ml insulin (Sigma-Aldrich) for MCF-7; EMEM (Sigma-Aldrich) for HeLa; L-15 (Roche) for MDA-MB-231 and MDA-MB-435S; MEGM (Cambrex Bio Science) for HMECs. Each medium was supplemented with 10% fetal bovine serum (Cansera International, Ontario, Canada) and 1% antibiotic/antimycotic solution (Sigma-Aldrich). MDA-MB-231 and MDA-MB-435S cells were maintained at 37degreesC in humidified air without CO2. Other cell lines were maintained at 37degreesC in humidified air with 5% CO2. Tissue samples from surgically resected breast cancers, and their corresponding clinical information, were obtained from the Department of Breast Surgery, Cancer Institute Hospital, Tokyo, after obtaining written informed consent.
###end p 17
###begin title 18
Semi-quantitative RT-PCR analysis
###end title 18
###begin p 19
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 451 492 451 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">glyceraldehyde-3-phosphate dehydrogenase </italic>
###xml 493 498 493 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 630 634 630 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK</italic>
###xml 701 706 701 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
Total RNAs were extracted from each microdissected breast cancer clinical sample and from microdissected normal ductal cells, and polyA(+) RNAs were isolated from normal mammary gland, lung, heart, liver, and kidney (Takara Clontech, Kyoto, Japan). Subsequently, T7-based amplification and reverse transcription were carried out as described previously [10]. We prepared appropriate dilutions of each single-stranded cDNA for subsequent PCR using the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene as a quantitative control. The PCR primer sequences were: 5'-GCTGCAAGGTATAATTGATGGA-3' and 5'-CAGTAACATAATGACAGATGGGC-3' for MELK; 5'-CGACCACTTTGTCAAGCTCA-3' and 5'-GGTTGAGCACAGGGTACTTTATT-3' for GAPDH.
###end p 19
###begin title 20
Northern blot analysis
###end title 20
###begin p 21
###xml 720 722 716 718 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 754 759 750 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 1072 1077 1062 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 638 643 <span type="species:ncbi:9606">human</span>
Total RNAs were extracted from breast cancer cell lines using the RNeasy kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. After treatment with DNase I (Nippon Gene, Osaka, Japan), mRNA was isolated with a mRNA purification kit (GE Healthcare, Buckinghamshire, United Kingdom) following the manufacturer's instructions. One microgram of each mRNA, along with polyA(+) RNAs isolated from normal mammary gland, lung, heart, liver, kidney and brain (Takara Clontech), were separated on 1% denaturing agarose gels and transferred to nylon membranes (breast cancer Northern blots). Breast cancer Northern blots and human multiple-tissue Northern blots (Takara Clontech) were hybridized with [alpha32P]-dCTP-labeled PCR products of MELK cDNA prepared by RT-PCR (see below). Pre-hybridization, hybridization and washing were performed according to the supplier's recommendations. The blots were autoradiographed with intensifying screens at -80degreesC for 12 days. A probe cDNA (542 base-pairs (bp)) for the sequence in the 3' untranslated region of MELK cDNA (GenBank accession number ) was prepared by PCR using the primer set 5'-TTATCACTGTGCTCACCAGGAG-3' and 5'-CAGTAACATAATGACAG ATGGGC-3' and were radioactively labeled using the megaprime DNA labeling system (GE Healthcare).
###end p 21
###begin title 22
cDNA library screening
###end title 22
###begin p 23
###xml 244 246 226 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 361 366 343 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
We constructed a cDNA library using polyA(+) RNA obtained from T47D breast cancer cells and the Superscripttrade mark plasmid system coupled with Gatewaytrade mark technology for cDNA synthesis and a cloning kit (Invitrogen). We screened 3 x 106 independent clones from this library with a cDNA probe corresponding to nucleotides 1,251 to 2,094 (843 bp) of the MELK cDNA sequence (GenBank accession number ).
###end p 23
###begin title 24
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
In vitro translation assay
###end title 24
###begin p 25
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 157 165 157 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 559 570 <span type="species:ncbi:3704">horseradish</span>
Three variants of MELK (V1, V2 and V3) that were cloned into the pSPORT-1 expression vector were used as templates for transcription/translation experiments in vitro. The plasmids (1 mug) were transcribed and translated using a TNT Coupled Reticulocyte Lysate system (Promega, Madison, WI, USA) in the presence of epsilon-labeled biotinylated lysine-tRNA according to the manufacturer's instructions. Proteins were electrophoresed by SDS-PAGE with a 5% to 20% gradient. After electroblotting, the biotinylated proteins were visualized by binding streptavidin-horseradish peroxidase followed by chemiluminescent detection (GE Healthcare).
###end p 25
###begin title 26
Plasmid construction
###end title 26
###begin p 27
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 161 164 161 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 171 174 171 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 364 370 364 370 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GAATTC</underline>
###xml 424 427 424 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 452 458 452 458 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTCGAG</underline>
###xml 510 513 510 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
To construct MELK expression vectors, the entire coding sequences were amplified by PCR using KOD-Plus DNA polymerase (Toyobo, Osaka, Japan) and cloned into the EcoRI and XhoI sites of the pCAGGSnHC expression vector in frame with the HA (hemagglutinin)-tag at the carboxyl terminus. The primer set used for PCR reactions with wild-type MELK-V1 was: forward, 5'-CGGAATTCACTATGAAAGATTATG ATGAAC-3' (underlining indicates the EcoRI site); reverse, 5'-AAACTCGAGTACCTTGCAGCTAGATAGGAT-3' (underlining indicates the XhoI site). Kinase-dead mutant MELK (D150A) was generated with a QuikcChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA) using the following primers; forward, 5'-CATAAATTAAAGCTGATTGCCTTTGGTCTCTGTGCAAAACC-3'; reverse: 5'-GGTTTTGCACAGAGACCAAAGGCAATCAGCTTTAATTTATG-3'.
###end p 27
###begin p 28
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-G</italic>
###xml 29 31 29 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L </italic>
###xml 29 31 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>L </italic></sub>
###xml 237 240 237 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Not</italic>
###xml 246 249 246 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 293 301 293 301 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GCGGCCGC</underline>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-G</italic>
###xml 344 346 344 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L </italic>
###xml 344 346 344 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>L </italic></sub>
###xml 367 373 367 373 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTCGAG</underline>
###xml 419 424 419 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-G</italic>
###xml 424 426 424 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L </italic>
###xml 424 426 424 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>L </italic></sub>
###xml 451 459 451 459 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GCGGCCGC</underline>
###xml 508 516 508 516 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GCGGCCGC</underline>
###xml 566 574 566 574 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GCGGCCGC</underline>
###xml 623 631 623 631 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GCGGCCGC</underline>
###xml 674 680 674 680 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTCGAG</underline>
###xml 733 739 733 739 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTCGAG</underline>
###xml 792 798 792 798 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTCGAG</underline>
###xml 1050 1053 1050 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Not</italic>
###xml 1059 1062 1059 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 118 123 <span type="species:ncbi:9606">human</span>
For construction of the Bcl-GL expression vectors, the corresponding open reading frame was generated by RT-PCR using human testis mRNA as a template and the following set of primers (underlining of forward and reverse primers indicates NotI and XhoI sites, respectively): forward, 5'-ATAAGAATGCGGCCGCGATGTGTAGCACCAGTGG-3' for full-length Bcl-GL (FL); reverse, 5'-CCGCTCGAGTTACTATCAGTCTACTTCTTCATGTG-3' for full-length Bcl-GL (FL); forward 5'-ATAAGAATGCGGCCGCGATCCCCCTAGATGATG-3' for N-1; forward 5'-ATAAGAATGCGGCCGCGTGGCCTTGCAGAAATTC-3' for N-2; forward 5'-ATAAGAATGCGGCCGCGGAATACCAAGATTCGC-3' for N-3; forward 5'-ATAAGAATGCGGCCGCGCAGGCAGGAGGCTTC-3' for N-4; reverse 5'-CCGCTCGAGTTACTATCAGAAGTTCTCTTTCAGGT-3' for C-1; reverse 5'-CCGCTCGAGTTACTATCATCTGGGGTCCACACCCA-3' for C-2; reverse 5'-CCGCTCGAGTTACTATCACAGCTCAACAATTTTGG-3' for C-3. The reverse primer of the FL construct was commonly used for N-1, N-2, N-3 and N-4 constructs, and the forward primer of it was commonly used for C-1, C-2 and C-3 constructs. These amplified DNAs were cloned into NotI and XhoI sites of the pCAGGSn3FH vector in frame with Flag-tag at the amino-terminal site. DNA sequences of all constructs were confirmed by DNA sequencing (ABI3700, PE Applied Biosystems, Foster, CA, USA).
###end p 28
###begin title 29
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
Gene-knockdown of MELK by siRNA
###end title 29
###begin p 30
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 212 216 212 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK</italic>
###xml 303 319 303 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Euglena gracilis</italic>
###xml 403 406 403 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bbs</italic>
###xml 519 538 519 538 <underline xmlns:xlink="http://www.w3.org/1999/xlink">ACTTGCCTGCCATATCCTT</underline>
###xml 547 566 547 566 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AAGGATATGGCAGGCAAGT</underline>
###xml 581 600 581 600 <underline xmlns:xlink="http://www.w3.org/1999/xlink">ACTTGCCTGCCATATCCTT</underline>
###xml 609 628 609 628 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AAGGATATGGCAGGCAAGT</underline>
###xml 647 666 647 666 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTATCCTGTTGAGTGGCAA</underline>
###xml 675 694 675 694 <underline xmlns:xlink="http://www.w3.org/1999/xlink">TTGCCACTCAACAGGATAG</underline>
###xml 709 728 709 728 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTATCCTGTTGAGTGGCAA</underline>
###xml 737 756 737 756 <underline xmlns:xlink="http://www.w3.org/1999/xlink">TTGCCACTCAACAGGATAG</underline>
###xml 775 794 775 794 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GACATCCTATCTAGCTGCA</underline>
###xml 803 822 803 822 <underline xmlns:xlink="http://www.w3.org/1999/xlink">TGCAGCTAGATAGGATGTC</underline>
###xml 837 856 837 856 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GACATCCTATCTAGCTGCA</underline>
###xml 865 884 865 884 <underline xmlns:xlink="http://www.w3.org/1999/xlink">TGCAGCTAGATAGGATGTC</underline>
###xml 903 922 903 922 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AGTTCATTGGAACTACCAA</underline>
###xml 931 950 931 950 <underline xmlns:xlink="http://www.w3.org/1999/xlink">TTGGTAGTTCCAATGAACT</underline>
###xml 965 984 965 984 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AGTTCATTGGAACTACCAA</underline>
###xml 993 1012 993 1012 <underline xmlns:xlink="http://www.w3.org/1999/xlink">TTGGTAGTTCCAATGAACT</underline>
###xml 1028 1047 1028 1047 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GCGCGCTTTGTAGGATTCG</underline>
###xml 1056 1075 1056 1075 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CGAATCCTACAAAGCGCGC</underline>
###xml 1090 1109 1090 1109 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GCGCGCTTTGTAGGATTCG</underline>
###xml 1118 1137 1118 1137 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CGAATCCTACAAAGCGCGC</underline>
###xml 1204 1209 1204 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 303 319 <span type="species:ncbi:3039">Euglena gracilis</span>
We established a vector-based RNA interference (RNAi) expression system using a psiH1BX3.0 small interfering (si)RNA expression vector as described previously [11]. siRNA expression vectors against MELK (psiH1BX-MELK) and scramble control (SC; the gene coding for 5S and 16S rRNAs in the chloroplast of Euglena gracilis; psiH1BX-SC) were prepared by cloning of double-stranded oligonucleotides into the BbsI site of the psiH1BX3.0 vector. The target sequence of synthetic oligonucleotides for siRNA were: si-#1, 5'-TCCCACTTGCCTGCCATATCCTTTTCAAGAGAAAGGATATGGCAGGCAAGT-3' and 5'-AAAAACTTGCCTGCCATATCCTTTCTCTTGAAAAGGATATGGCAGGCAAGT-3', si-#2, 5'-TCCCCTATCCTGTTGAGTGGCAATTCAAGAGATTGCCACTCAACAGGATAG-3' and 5'-AAAACTATCCTGTTGAGTGGCAATCTCTTGAATTGCCACTCAACAGGATAG-3', si-#3, 5'-TCCCGACATCCTATCTAGCTGCATTCAAGAGATGCAGCTAGATAGGATGTC-3' and 5'-AAAAGACATCCTATCTAGCTGCATCTCTTGAATGCAGCTAGATAGGATGTC-3', si-#4, 5'-TCCCAGTTCATTGGAACTACCAATTCAAGAGATTGGTAGTTCCAATGAACT-3' and 5'-AAAAAGTTCATTGGAACTACCAATCTCTTGAATTGGTAGTTCCAATGAACT-3'. SC, 5'-TCCCGCGCGCTTTGTAGGATTCGTTCAAGAGACGAATCCTACAAAGCGCGC-3' and 5'-AAAAGCGCGCTTTGTAGGATTCGTCTCTTGAACGAATCCTACAAAGCGCGC-3'. Underlining indicates siRNA-targeting sequences designed from MELK mRNA (GenBank accession number ). All constructs were also confirmed by DNA sequencing.
###end p 30
###begin p 31
###xml 82 84 82 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 136 141 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 431 433 430 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 512 514 511 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 568 570 567 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 707 711 706 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK</italic>
###xml 1064 1069 1062 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 1077 1081 1072 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2MG </italic>
###xml 1382 1386 1377 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK</italic>
###xml 1454 1458 1446 1450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2MG </italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human breast cancer cells lines T47D and MCF-7 were plated in 15 cm dishes (4 x 106 cells/dish), and transfected with 16 mug of psiH1BX-MELK (si-#1, si-#2, si-#3 and si-#4) and psiH1BX-SC (SC; negative control) siRNA plasmids using the FuGENE6 transfection reagent (Roche) according to the supplier's recommendations. At 24 hours after transfection, cells were re-seeded for the following experiments at the densities given: 1 x 106 cells/10 cm dish for semi-quantitative RT-PCR and western blot analyses; 3 x 106 cells/10 cm dish for colony formation assay and 5 x 105 cells/well for MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. We selected T47D or MCF7 cells transfected with MELK-siRNAs in medium containing 0.7 mg/ml or 0.6 g/ml neomycin (geneticine; Invitrogen), respectively. Four days after neomycin selection, 0.5 mug of total RNA extracted from these cells was reverse-transcribed into cDNA using Superscript II (Invitrogen) to examine the knockdown effect of siRNAs by semi-quantitative RT-PCR using specific primer sets for MELK and beta2MG (encoding beta-2-microglobulin). Cells were also harvested four days after neomycin selection for western blot analysis using anti-MELK antibody (Cell signaling technology, Boston, MA, USA). The specific primer sets for RT-PCR were: 5'-TTATCACTGTGCTCACCAGGAG-3' and 5'-CAGTAACATAAT GACAGATGGGC-3' for MELK; 5'-TTAGCTGTGCTCGCGCTACT-3' and 5'-TCACATGGTTCACACGGCAG-3' for beta2MG as a quantitative control. Transfectants expressing siRNA were grown for 3 weeks in selective media containing neomycin, then fixed with 4% paraformaldehyde for 15 minutes before staining with Giemsa's solution (Merck, Whitehouse Station, NJ, USA) to assess colony number. To quantify cell viability, MTT assays were performed at seven days after selection with Cell Counting Kit-8 (Wako, Osaka, Japan) according to the manufacture's protocols. Absorbance at 570 nm was measured with a Microplate Reader 550 (Bio-Rad, Hercules, CA, USA). These experiments were performed in triplicate.
###end p 31
###begin title 32
Generation and purification of His-tagged recombinant MELK
###end title 32
###begin p 33
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 359 376 359 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 517 518 517 518 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 527 528 527 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 539 540 539 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 542 543 542 543 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 552 553 552 553 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 556 557 556 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 868 870 861 863 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 973 975 966 968 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1012 1029 1005 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 1310 1312 1303 1305 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1357 1359 1350 1352 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 359 387 <span type="species:ncbi:511693">Escherichia coli strain BL21</span>
###xml 1012 1040 <span type="species:ncbi:511693">Escherichia coli strain BL21</span>
The entire coding sequences of wild-type MELK (WT-MELK) and kinase-dead MELK (D150A-MELK; asparate changed to alanine at the 150th residue in the kinase subdomain VII, which is considered as the ATP binding site [12]) were subcloned into the pET21a vector (Merck Novagen, Darmstadt, Germany). The WT-MELK and D150A-MELK recombinant proteins were expressed in Escherichia coli strain BL21 codon-plus (DE3) RIL competent cells (Stratagene), and cultured in TBG-M9 medium (1% tryptone, 0.5% NaCL, 0.5% glucose, 1 mM MgSO4, 0.1% NH4CI, 0.3% KH2PO4, 0.6% Na2HPO4). After induction with 0.5 muM isopropyl-b-D-thiogalactopyranoside (IPTG) at 25degreesC for 5 hours, the bacteria pellet was suspended with lysis buffer, and was purified with Ni-NTA superflow (Qiagen) under nondenaturing conditions according to the supplier's instructions. The entire coding sequence of BCL-GL was also subcloned into the pGEX-6P-1 vector (GE Healthcare). The glutathione S-transferase (GST)-Bcl-GL recombinant protein was expressed in Escherichia coli strain BL21 codon-plus RIL competent cells (Stratagene). Purification of the recombinant proteins was performed using Glutathione Sepharose 4B beads (GE Healthcare) under nondenaturing conditions according to the supplier's instructions. For confirmation of direct binding of BCL-GL and MELK, we removed GST from GST-fused BCL-GL protein using PreScission protease (GE Healthcare) according to the supplier's instructions.
###end p 33
###begin title 34
Protein pull down assay
###end title 34
###begin p 35
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 473 474 471 472 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
HBC4 cells were lysed with lysis buffer (40 mM Tris-HCL (pH 7.5), 1% Trition X-100, 2.5 mM EDTA, 15 mM dithiothreitol (DTT)) including 0.1% protease inhibitor cocktail III (Calbiochem, San Diego, CA, USA) as previously described [13] with a minor modification. We incubated 7.5 mg of cell lysates with 0.5 muM of WT-MELK or D150A-MELK recombinant proteins pre-immobilized on Ni-NTA agarose beads in reaction buffer containing 50 mM Tris-HCL (pH 7.5), 50 muM ATP, 10 mM MgCL2, 25 mM NaCL and 1 mM DTT at 30degreesC for 5 minutes. The protein-bound beads were washed three times with lysis buffer, and then eluted with SDS sample buffer. The proteins were separated by SDS-PAGE using a 4% to 12% gradient Bis-Tris gel (Invitrogen), and stained with Silver Stain DAIICHI (Daiichi Pure Chemicals, Tokyo, Japan). An approximately 30 kDa band, which was seen in pulled-down cell lysates with WT-MELK added but not in those with D150A-MELK added, was extracted. Its peptide sequence was determined by MALDI-TOF mass spectrometry.
###end p 35
###begin title 36
Western blot analysis
###end title 36
###begin p 37
###xml 39 41 39 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 931 933 931 933 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1067 1078 <span type="species:ncbi:3704">horseradish</span>
To detect the endogenous MELK and Bcl-GL proteins in breast cancer cell lines (BT-20, HBC4, HBC5, HBL100, MCF-7, MDA-MB-231, SKBR3 and T47D) and HMECs, these cells were lysed in lysis buffer (50 mM Tris-HCL pH 8.0, 150 mM NaCL, 0.5% NP-40) including 0.1% protease inhibitor cocktail III (Calbiochem). After homogenization, the cell lysates were incubated on ice for 30 minutes and centrifuged at 14,000 rpm for 15 minutes to separate only supernatant from cell debris. The amount of total protein was estimated by protein assay kit (Bio-Rad), and the proteins were then mixed with SDS sample buffer and boiled for 3 minutes before loading into a 10% to 20% gradient SDS-PAGE gel (Bio-Rad). After electrophoresis, the proteins were transferred onto nitrocellulose membrane (GE Healthcare). Membranes were blocked by 4% BlockAce (Dainippon Pharmaceutical Co., Ltd, Osaka, Japan), and incubated with anti-MELK polyclonal or anti-Bcl-GL polyclonal antibodies (Abcam, Cambridge, MA, USA). beta-Actin served as a loading control. Finally, the membranes were incubated with horseradish peroxidase (HRP) conjugated secondary antibody and protein bands were visualized by enhanced chemiluminescence (ECL) detection reagents (GE Healthcare).
###end p 37
###begin title 38
Co-immunoprecipitation assay
###end title 38
###begin p 39
###xml 127 129 126 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 169 171 168 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 433 438 <span type="species:ncbi:10090">mouse</span>
HeLa cells were transiently co-transfected for 48 hours with 8 mug of plasmid constructs encoding Flag-tagged full-length Bcl-GL or a series of Flag-tagged partial Bcl-GL proteins (FL, N-1, N-2, N-3, N-4, C-1, C-2 and C-3) as well as the same amount of plasmid encoding HA-tagged WT-MELK, using the FuGENE6 transfection reagent (Roche). Cells were lysed with lysis buffer as described above. The lysates were pre-cleaned with normal mouse IgG (1.2 mug) and rec-Protein G Sepharose 4B (Zymed, San Francisco, CA, USA) at 4degreesC for 30 minutes. Subsequently, the lysate was incubated with anti-Flag agarose M2 gel (Sigma-Aldrich) at 4degreesC for 12 hours. After washing three times with lysis buffer, proteins on beads were eluted with SDS sample buffer.
###end p 39
###begin title 40
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
In vitro binding assay
###end title 40
###begin p 41
###xml 202 203 199 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 565 566 554 555 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 691 693 678 680 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 862 863 843 844 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1071 1073 1052 1054 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 581 587 <span type="species:ncbi:9913">bovine</span>
The His-tagged MELK recombinant protein (10 mug) was immunoprecipitated with anti-6XHis-tag monoclonal antibody (2 mug; Takara Clontech) in 500 mul of coupling buffer (50 mM Tris, 75 mM NaCL, 10 mM MgCL2, 1 mM DTT, and complete EDTA-free protease inhibitors; Roche) for 3 hours at 4degreesC. Subsequently, 30 mul of protein G Sepharose (Zymed) was added, and the incubation was further continued for 45 minutes. The immune complexes were washed 3 times with 1 ml of coupling buffer, and resuspended with 500 mul of binding buffer (50 mM Tris, 75 mM NaCL, 10 mM MgCL2, 1 mM DTT, 2% bovine serum albumin, 100 muM ATP and complete EDTA-free protease inhibitors; Roche) containing 5 mug of Bcl-GL recombinant protein. After incubation for 30 minutes at 4degreesC for binding, the samples were washed 5 times with washing buffer (50 mM Tris-CL, 75 mM NaCL, 10 mM MgCL2, 1 mM DTT, 0.01% Triton-X100 and complete EDTA-free protease inhibitors; Roche). The precipitates were then eluted with SDS sample buffer by boiling for 3 minutes and analyzed by western blot with anti-Bcl-GL antibody.
###end p 41
###begin title 42
Immunocomplex kinase assay
###end title 42
###begin p 43
###xml 29 31 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 110 112 110 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 847 849 832 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1073 1075 1049 1051 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 1112 1113 1088 1089 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 567 573 <span type="species:ncbi:9986">rabbit</span>
To use the long isoform Bcl-GL recombinant protein as a substrate for kinase assay, a set of Flag-tagged Bcl-GL (FL, N-1, N-2 N-3 and N-4) expression vectors was transfected into HeLa cells, and the proteins were immunoprecipitated with Flag-conjugated agarose M2 gel (Sigma-Aldrich) at 4degreesC for 1 hour. These immunoprecipitates were washed five times with lysis buffer containing 50 mM Tris-HCL (pH 7.5), 150 mM NaCL, 1% NP-40 and 0.1% protease inhibitor cocktail III (Calbiochem). Aliquots (20 mul) of immunoprecipitates were subjected to immunoblotting using rabbit anti-Flag antibody (Sigma-Aldrich) to check the success of the immunoprecipitation experiments. His-tagged MELK recombinant proteins (0.5 muM WT-MELK and D150A-MELK) were reacted for 30 minutes at 30degreesC with aliquots (20 mul) of immunoprecipitates of Flag-tagged Bcl-GL (FL, N-1 N-2, N-3 and N-4) as substrates in 50 mul of kinase buffer containing 30 mM Tris-HCL (pH 7.5), 0.1 mM EGTA, 10 mM DTT, 40 mM NaF, 40 mM sodium beta-glycerophosphate (Sigma-Aldrich), 50 muM cold-ATP, 10 Ci of [gamma-32P] ATP (GE Healthcare) and 10 mM MgCL2. The reaction was terminated by addition of SDS sample buffer and boiled for 3 minutes prior to 10% SDS-PAGE. The gel was then dried and autoradiographed with intensifying screens at room temperature overnight.
###end p 43
###begin title 44
TUNEL assay for apoptosis
###end title 44
###begin p 45
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 102 104 101 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 401 403 400 402 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 411 413 410 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 565 573 563 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In situ </italic>
COS7 cells (1 x 106) were co-transfected with 8 mug each of Flag-tagged pCAGGSn3FH vectors (Flag-Bcl-GL and Flag-Mock) and HA-tagged pCAGGSnHC vectors (HA-WT-MELK, HA-D150A-MELK and HA-Mock) using the FuGENE 6 transfection reagent (Roche) according to the supplier's protocol. At 24 hours post-transfection, cells were harvested by trypsinization and washed with phosphate buffered saline without CaCL2 and MgCL2 (PBS(-)). An aliquot of cells (300 mul) was immobilized on the microslide glass (Matsunami Glass, Osaka, Japan) and subjected to a TUNEL assay using an In situ Cell Death Detection Kit, Fluorescein (Roche) according to the supplier's instructions. The apoptotic cells were observed with a TCS SP2 AOBS microscope (Leica, Tokyo, Japan). Experiments were carried out in triplicate independently.
###end p 45
###begin title 46
Flow cytometry analysis for apoptosis
###end title 46
###begin p 47
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 102 104 101 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
COS7 cells (1 x 106) were co-transfected with 8 mug each of Flag-tagged pCAGGSn3FH vectors (Flag-Bcl-GL and Flag-Mock) and HA-tagged pCAGGSnHC vectors (HA-WT-MELK, HA-D150A-MELK and HA-Mock) using the FuGENE 6 transfection reagent (Roche). For FACS analysis, the cells were harvested by trypsinization and fixed with 70% ethanol at room temperature for 30 minutes. After centrifuging to remove the ethanol, the cells were treated with 0.5 ml of PBS(-) containing 1 mg/ml of RNase I (Sigma-Aldrich) for 30 minutes followed by staining in 1 ml of PBS(-) containing 20 mg/ml of propidium iodide (Sigma-Aldrich) for 30 minutes. The cells selected from at least 10,000 ungated cells were analyzed for DNA content by flow cytometry (FACS calibur; Becton Dickinson, San Diego, CA, USA). The data were analyzed using CELLQuest software (FACS calibur; Becton Dickinson). Assays were done in triplicate independently.
###end p 47
###begin title 48
Statistical analysis
###end title 48
###begin p 49
###xml 53 54 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 136 138 136 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Statistical significance was determined by Student's t-test using Statview 5.0 software (SAS Institute, Cary, NC, USA). A difference of P < 0.05 was considered to be statistically significant.
###end p 49
###begin title 50
Results
###end title 50
###begin title 51
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
Up-regulation of MELK in breast cancer
###end title 51
###begin p 52
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 264 269 264 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 529 534 529 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
We previously reported the genome-wide expression profile analysis of 81 clinical breast cancers, representing 23,040 genes, by means of cDNA microarray analysis in combination with enrichment of cancer cells with a laser microbeam microdissection system [8]. The MELK gene (GenBank accession number ) was found to be one of the genes transactivated at a very high level in the great majority of the breast cancers examined. The subsequent semi-quantitative RT-PCR analysis of the transcript confirmed the elevated expression of MELK in 11 of 12 clinical breast cancer specimens (Figure 1a).
###end p 52
###begin p 53
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 164 169 <span type="species:ncbi:9606">human</span>
To further examine the expression pattern of this gene in breast cancer cell lines and normal tissues, we performed Northern blot analyses with mRNAs from multiple human tissues and breast cancer cell lines using a cDNA fragment corresponding to the 3' untranslated region of the MELK gene as a probe. The results showed that an approximately 2.7 kb band was most highly expressed in testis, and weakly expressed in thymus and small intestine (Figure 1b). Interestingly, Northern blot analyses of breast cancer cell lines using the same probe showed that 2.4 to 2.7 kb bands were significantly over-expressed in breast cancer cells but were not expressed in vital organs (Figure 1c), indicating that some cancer specific transcripts are present over this range.
###end p 53
###begin p 54
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d</xref>
###xml 982 991 982 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1178 1180 1178 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1e</xref>
To characterize the variants specifically transcribed in breast cancer cells, we screened a cDNA library of breast cancer cells. Subsequent cDNA sequencing analysis identified three different transcriptional variants, designated V1 (2,501 bp; NM_014791), V2 (2,368 bp; AB183427) and V3 (2,251 bp; AB183428). These three different transcriptional variants consist of 18, 17 and 16 exons, respectively. The V2 variant lacks exon 3 (86 bp) and the V3 variant lacks exon 3 (86 bp) and exon 4 (117 bp) as a result of alternative splicing (Figure 1d). The V2 and V3 variants contain early stop codons (TGA) in exon 4 and exon 5, respectively, if they are translated from the same first ATG codon of the V1 variant. However, if they are translated from a second ATG codon located downstream of the first ATG codon of the V1 variant, the V2 and V3 variant proteins are thought to produce 618 and 581 amino acid peptides, respectively. Thus, to examine both possibilities, we carried out an in vitro translation assay and found that the V1, V2 and V3 proteins were 75, 71 and 66 kDa, respectively, indicating that the V2 and V3 proteins were translated from the second ATG codon (Figure 1e).
###end p 54
###begin p 55
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1f</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1g</xref>
Subsequently, we examined MELK expression in breast cancer cell lines by western blot analysis with anti-MELK polyclonal antibodies. The results indicate that the V1 protein is dominantly overexpressed in breast cancer cells compared with the V2 and V3 proteins (Figure 1f). Furthermore, although all of the three variant proteins possess the KA1 domain in their carboxyl terminus, the V2 and V3 proteins lack the amino-terminal portion, which corresponds to the first 48 amino acids of the V1 protein and is considered to be the catalytic kinase domain (Figure 1g). Although we can not rule out the possibility that the V2 and V3 variants have some functional role in carcinogenesis, for example, dominant-negative functions, in this study we focus on the kinase activity of the V1 transcript due to its predominant expression in cancer cells.
###end p 55
###begin title 56
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK</italic>
Growth-inhibitory effects of siRNA against MELK
###end title 56
###begin p 57
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a,b</xref>
###xml 181 186 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 337 342 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 416 420 416 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK</italic>
###xml 582 583 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 727 729 727 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 739 741 739 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 761 763 761 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 773 775 773 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 794 795 794 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 905 910 905 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
To assess a possible role of MELK in mammary carcinogenesis, we knocked down the expression of endogenous MELK in the breast cancer cell lines T47D and MCF7 (Figure 2a,b), in which MELK was overexpressed at a high level, by means of the mammalian vector-based RNAi technique (see Materials and methods). We examined expression levels of MELK by semi-quantitative RT-PCR and western blot analyses, and found that the MELK-siRNAs si-#3 and si-#4 significantly reduced its expression at the transcriptional and protein levels compared with scramble-siRNA (SC), si-#1 and si-#2 (Figure 2). Colony formation and MTT assays revealed that both si-#3 and si-#4 significantlysuppressed growth of T47D and MCF7 cells (MTT assay in T47D, P = 0.0003, P = 0.0013; in MCF-7, P = 0.0001, P = 0.0001; unpaired t-test), in concordance with the results showing the knockdown effect of this gene. These results suggest that MELK has a critical role in the growth of breast cancer cells.
###end p 57
###begin title 58
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
Identification of Bcl-GL as a MELK-interacting protein
###end title 58
###begin p 59
###xml 126 135 126 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 649 655 649 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-G </italic>
###xml 703 709 703 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-G </italic>
###xml 724 729 724 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-G</italic>
###xml 729 730 729 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 729 730 729 730 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>S</italic></sub>
###xml 749 754 749 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-G</italic>
###xml 754 755 754 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 754 755 754 755 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>m</italic></sub>
###xml 775 780 775 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-G</italic>
###xml 780 781 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L</italic>
###xml 780 781 780 781 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>L</italic></sub>
To investigate the biological functions of MELK in breast cancer cells, we searched for substrates of MELK in cancer cells by in vitro protein pull-down assays using wild-type MELK (WT-MELK) and kinase-dead MELK (D150A-MELK) recombinant proteins. Comparison of silver staining of SDS-PAGE gels containing the pulled-down proteins identified an approximately 30 kDa protein in the lane corresponding to proteins pulled-down with WT-MELK but not in that corresponding to proteins pulled-down with D150A-MELK (Figure 3a). MALDI-TOF analysis showed this 30 kDa protein to be Bcl-G, a member of the Bcl-2 protein family [14]. According to NCBI database, Bcl-G has three alternative splicing isoforms, termed Bcl-G short isoform (Bcl-GS), median isoform (Bcl-Gm) and long isoform (Bcl-GL), and encoding 252, 276 and 327 amino acid peptides, respectively.
###end p 59
###begin p 60
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-G </italic>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-G</italic>
###xml 172 174 172 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S </italic>
###xml 172 174 172 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>S </italic></sub>
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-G</italic>
###xml 183 185 183 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L </italic>
###xml 183 185 183 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>L </italic></sub>
###xml 249 254 249 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-G</italic>
###xml 254 256 254 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m </italic>
###xml 254 256 254 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>m </italic></sub>
###xml 364 366 364 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 459 461 459 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 523 524 523 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 684 686 684 686 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
We first examined the expression patterns of these Bcl-G isoforms at the transcriptional level in breast cancer cell lines by semi-quantitative RT-PCR, and found that Bcl-GS and Bcl-GL were expressed in all breast cancer cells examined, whereas the Bcl-Gm transcript was not detected at all (data not shown). Furthermore, we examined expression of endogenous Bcl-GL in breast cancer cell lines at the protein level by western blot analysis using an anti-Bcl-GL antibody and detected an approximately 30 kDa endogenous Bcl-GL, corresponding to the size identified by protein pull-down experiment, in all the breast cancer cell lines examined (Figure 3b). Therefore, we focused on Bcl-GL as a candidate interacting protein for MELK.
###end p 60
###begin p 61
###xml 52 53 52 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 151 153 151 153 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 164 165 164 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 365 367 365 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 495 497 495 497 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 551 559 551 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 566 568 566 568 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 680 682 680 682 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 788 790 788 790 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 824 826 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3e</xref>
###xml 1083 1085 1083 1085 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1222 1224 1222 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3f</xref>
###xml 1319 1321 1319 1321 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1435 1437 1435 1437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3f</xref>
###xml 1524 1526 1524 1526 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
To validate an interaction between WT-MELK and Bcl-GL, we constructed plasmids designed to express HA-tagged WT-MELK (HA-WT-MELK) and Flag-tagged Bcl-GL (Flag-Bcl-GL). These plasmids were co-transfected into HeLa cells and the proteins immunoprecipitated with anti-Flag antibody. Immunoblotting of the precipitates using anti-HA antibodies indicated that Flag-Bcl-GL was co-precipitated with HA-WT-MELK (Figure 3c). Furthermore, we demonstrated that His-tagged WT-MELK could pull-down with Bcl-GL but His-tagged D150A-MELK could not, indicating that, in vitro, Bcl-GL interacts directly with WT-MELK but not with D150A-MELK (Figure 3d). To further determine which segment of Bcl-GL can interact with WT-MELK, we performed co-immunoprecipitation analyses using HA-WT-MELK and partial Bcl-GL proteins tagged with Flag (Figure 3e). After co-transfection of plasmid clones into HeLa cells, we performed immunoprecipitation with an anti-Flag antibody, and then immunoblotting with an anti-HA antibody. We found that the N-1 construct (amino acids 12 to 327) as well as a full-length Bcl-GL (FL) bound to WT-MELK, whereas N-2 (amino acids 72 to 324), N-3 (amino acids 121 to 327) or N-4 (amino acids 171 to 327) did not (Figure 3f). Concordantly, all of the partial products that contained the amino-terminal portion of Bcl-GL - C-1 (amino acids 1 to 305), C-2 (amino acids 1 to 295), and C-3 (amino acids 1 to 215) bound to WT-MELK (Figure 3f). These results suggest that the region corresponding to amino acids 12 to 71 of Bcl-GL is likely to interact with WT-MELK.
###end p 61
###begin title 62
###xml 25 26 25 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
MELK phosphorylates Bcl-GL
###end title 62
###begin p 63
###xml 28 30 28 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 187 189 187 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 200 201 200 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3f</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 297 298 297 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 539 541 539 541 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 627 628 627 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 663 665 663 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
To examine whether the Bcl-GL protein is a substrate of MELK kinase activity, we performed an immune complex kinase assay. We first confirmed the exogenous expression of Flag-tagged Bcl-GL (Flag-Bcl-GL) by western blot analysis (Figure 3f). As shown in Figure 4a, WT-MELK could phosphorylate Bcl-GL, but D150A-MELK could not (single arrowhead). In addition, autophosphorylation of an approximately 75 kDa protein of MELK was observed (Figure 4a; double arrowheads). Furthermore, we also confirmed that WT-MELK could phosphorylate GST-Bcl-GL but D150A-MELK could not (Figure 4b), indicating MELK can directly phosphorylate Bcl-GL. These findings suggest that Bcl-GL is a potential substrate for MELK.
###end p 63
###begin p 64
###xml 88 90 88 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3e</xref>
###xml 203 205 203 205 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 260 262 260 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3f</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
###xml 448 449 448 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
We subsequently examined WT-MELK kinase activity on various partial amino-terminal Bcl-GL products (Figure 3e). First, we confirmed the amount of immunoprecipitated protein corresponding to partial Bcl-GL (N-1, N-2, N-3 and N-4) as well as to full-length Bcl-GL (FL) by western blot analysis (Figure 3f), and then examined the extent of their phosphorylation (Figure 4c). The MELK recombinant protein phosphorylated N-1 as well as full-length Bcl-GL, whereas it could not phosphorylate N-2, N-3 or N-4 proteins, corresponding with their inability to interact.
###end p 64
###begin title 65
###xml 55 56 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
MELK involvement in the apoptotic pathway through Bcl-GL
###end title 65
###begin p 66
###xml 65 67 65 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 172 173 172 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 342 344 342 344 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 547 549 547 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 624 628 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b,c</xref>
###xml 669 671 669 671 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 690 691 690 691 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 857 859 857 859 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 903 905 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 964 966 964 966 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 988 989 988 989 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 1076 1078 1076 1078 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1103 1104 1103 1104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 1107 1109 1107 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1128 1129 1128 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1192 1194 1192 1194 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1219 1220 1219 1220 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 1296 1298 1296 1298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5d</xref>
###xml 1400 1402 1400 1402 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1558 1560 1558 1560 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1600 1602 1600 1602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1619 1620 1619 1620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1810 1811 1810 1811 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
Because MELK can physically interact with and phosphorylate Bcl-GL (Figures 3d and 4a), we hypothesized that it might be involved in the apoptosis cascade through the Bcl-GL-related pathway. To investigate this hypothesis, we transiently co-transfected two plasmid clones designed to express HA-tagged MELK (WT or D150A) and Flag-tagged Bcl-GL into COS7 cells, and then performed a TUNEL assay and FACS analysis to measure the proportions of apoptotic cells (see Material and methods). We first confirmed the exogenous expression of MELK and Bcl-GL in COS7 cells by western blot analysis (Figure 5a). As indicated in Figure 5b,c, the overexpression of full-length Bcl-GL (HA-Mock+Flag-Bcl-GL) significantly increased the proportion of TUNEL-positive cells compared with the cells transfected with the mock plasmids (HA-Mock+Flag-Mock), indicating that Bcl-GL induces apoptosis, as described previously [14]. In contrast, the co-overexpression of WT-MELK with Bcl-GL (HA-WT-MELK+Flag-Bcl-GL) reduced the proportion of TUNEL-positive cells compared with over-expression of Bcl-GL alone (HA-Mock+Flag-Bcl-GL) (P = 0.0001, unpaired t-test). However, the co-overexpression of D150A-MELK with Bcl-GL (HA-D150A-MELK+Flag-Bcl-GL) did not affect the proportion of TUNEL-positive cells. As shown in Figure 5d, FACS analysis of the cells under the same conditions also confirmed that the overexpression of Bcl-GL increased the sub-G1 population of cells compared with the mock-transfected cells. Similarly to the TUNEL analysis, the overexpression of WT-MELK with Bcl-GL reduced the proportion of sub-G1 cells (P = 0.03, unpaired t-test), while D150A-MELK increased the sub-G1 population. Our results imply that the kinase activity of MELK may play a critical role in the regulation of the pro-apoptotic function of Bcl-GL.
###end p 66
###begin title 67
Discussion
###end title 67
###begin p 68
###xml 480 488 <span type="species:ncbi:9606">patients</span>
Microarray technologies applied to the study of cancer have contributed to the discovery of genes that play essential roles in carcinogenesis, the discovery of novel molecular target(s) for the development of anti-cancer agents and/or diagnosis, and the identification of genes related to chemo- or radio-sensitivity. Although such information has been applied in the development of novel therapeutic agents for breast cancer, the range of available treatments for advanced-stage patients is still very limited. Thus, it is urgent that further molecular targets are discovered to enable development of new anti-cancer drugs that are specific for malignant cells with a minimum risk of adverse reactions.
###end p 68
###begin p 69
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 84 85 84 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK</italic>
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 262 267 <span type="species:ncbi:9606">human</span>
Using genome-wide expression profiles of breast cancers and normal human tissues [8,9], we identified MELK, one of the transcripts of which was specifically up-regulated in the great majority of clinical breast cancer samples, but expressed in none of 29 normal human tissues examined except testis, thymus and small intestine.
###end p 69
###begin p 70
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 428 433 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 593 598 593 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
In this study, we characterize the biological function of MELK and indicate that it would be a good candidate as a molecular target for breast cancer therapy, although there would be some concerns over intestinal adverse reactions. We demonstrated by means of siRNA that knockdown of endogenous MELK expression results in growth suppression of breast cancer cells (Figure 2). Furthermore, our cDNA microarray data indicate that MELK is also up-regulated relatively frequently in bladder cancers, osteosarcoma and small cell lung cancers (data not shown). Together, these findings suggest that MELK has an oncogenic role in not only breast cancers but also bladder cancers, bone cancers and small cell lung cancers.
###end p 70
###begin p 71
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 551 556 551 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 770 779 770 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 917 918 917 918 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 1064 1073 1064 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1099 1108 1099 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1140 1142 1140 1142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1207 1216 1207 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1225 1227 1225 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 1232 1236 1232 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a,b</xref>
MELK was previously identified as a new member of the snf1/AMPK serine-threonine kinase family that is involved in mammalian embryonic development [15-18]. This gene was shown to play an important role in hematopoiesis, stem cell renewal [19] and cell-cycle progression through an interaction with zinc finger-like protein ZPR9 [20] and splicing factor NIPP1 [12]. To investigate the expression pattern of these proteins in breast cancer cells, we performed semi-quantitative RT-PCR, and observed no significant correlation of gene expression between MELK and these interacting molecules in breast cancer cells (data not shown). Thus, to investigate the biological significance of MELK in breast cancer cells, we searched for a possible substrate(s) of MELK by means of in vitro pull-down assays with recombinant wild-type MELK (WT-MELK) and kinase-dead MELK (D150A-MELK). We identified a long isoform of Bcl-G (Bcl-GL), a pro-apoptotic member of the Bcl-2 family, as a potential substrate for MELK. In addition to physical interaction between these two proteins, in vitro immune complex kinase and in vitro binding assays showed that Bcl-GL was directly bound to MELK and specifically phosphorylated by it in vitro (Figures 3d and 4a,b).
###end p 71
###begin p 72
###xml 24 26 24 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 116 118 116 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 261 262 261 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 307 311 307 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b&#8211;d</xref>
###xml 418 420 418 420 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
As reported previously [14], we demonstrated by TUNEL assay and FACS analysis that introduction of full-length Bcl-GL into COS7 cells induced apoptosis. However, under the same conditions, addition of exogenous WT-MELK suppressed induction of apoptosis by Bcl-GL, but addition of D150A-MELK did not (Figure 5b-d). Thus, we speculate that MELK might promote cell growth by inhibiting the pro-apoptotic function of Bcl-GL through its phosphorylation.
###end p 72
###begin title 73
Conclusion
###end title 73
###begin p 74
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 403 408 403 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 635 640 635 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 750 751 750 751 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 894 899 894 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
Our findings clearly suggest that MELK is overexpressed in both breast cancer specimens and cancer cell lines, and that its kinase activity possibly plays a significant role in breast cancer cell growth. Recent anti-cancer drug development is focused on targeting important molecules involved in the oncogenic pathways, represented by imatinib mesylate and trastuzumab. We found that down-regulation of MELK by treatment with siRNA significantly suppressed the cell growth of breast cancer, indicating its crucial role in the proliferation and tumorgenesis of breast cancer. In particular, we demonstrate a new biological function for MELK in breast carcinogenesis, the inhibition of apoptosis though its interaction with and phosphorylation of Bcl-GL, a pro-apoptotic member of Bcl-2 family. Our data should contribute to a better understanding of breast carcinogenesis, and they suggest that MELK is a promising molecular target for breast cancer treatment.
###end p 74
###begin title 75
Abbreviations
###end title 75
###begin p 76
###xml 136 141 <span type="species:ncbi:9606">human</span>
beta2MG = beta-2-microglobulin; DTT = dithiothreitol; GST = glutathione S-transferase; Her-2/ErbB-2 = epidermal growth factor 2; HMEC = human mammary epithelial cell; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PBS = phosphate-buffered saline; RNAi = RNA interference; SC = scramble control.
###end p 76
###begin title 77
Competing interests
###end title 77
###begin p 78
The authors declare that they have no competing interests.
###end p 78
###begin title 79
Authors' contributions
###end title 79
###begin p 80
LML performed all experiments and drafted the manuscript. PJH participated in the discussion and interpretation of data. NT constructed expression profiles of breast cancer and participated in the screening of candidate genes. YN was involved in the conception and design of studies, interpretation of data and preparing the final version of the manuscript. TK guided all molecular aspects of the studies and was involved in the design of studies and interpretation of results.
###end p 80
###begin title 81
Acknowledgements
###end title 81
###begin p 82
We thank Ms Kyoko Kijima and Ms Akiko Konuma for excellent technical assistance, Ms Yuria Mano for a screening of candidate genes for breast cancer therapy, Dr Akira Togashi and Mr Ryuichiro Tobita for confirmation of MELK expression by real-time PCR and western blot analyses, and Drs Arata Shimo, Tomomi Ueki, Chikako Fukukawa and Miki Akiyama for helpful discussions.
###end p 82
###begin article-title 83
Breast cancer
###end article-title 83
###begin article-title 84
A pooled analysis of bone marrow micrometastasis in breast cancer
###end article-title 84
###begin article-title 85
Pathological validation and significance of micrometastasis in sentinel nodes in primary breast cancer
###end article-title 85
###begin article-title 86
Pharmacological breast cancer therapy (review)
###end article-title 86
###begin article-title 87
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
###end article-title 87
###begin article-title 88
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study
###end article-title 88
###begin article-title 89
###xml 139 144 <span type="species:ncbi:9606">women</span>
Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women
###end article-title 89
###begin article-title 90
Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis
###end article-title 90
###begin article-title 91
###xml 54 59 <span type="species:ncbi:9606">human</span>
Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray
###end article-title 91
###begin article-title 92
Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia
###end article-title 92
###begin article-title 93
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF18 </italic>
Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex
###end article-title 93
###begin article-title 94
Inhibition of spliceosome assembly by the cell cycle-regulated protein kinase MELK and involvement of splicing factor NIPP1
###end article-title 94
###begin article-title 95
A novel method to identify protein kinase substrates: eEF2 kinase is phosphorylated and inhibited by SAPK4/p38delta
###end article-title 95
###begin article-title 96
Bcl-G, a novel pro-apoptotic member of the Bcl-2 family
###end article-title 96
###begin article-title 97
###xml 54 64 <span type="species:ncbi:7955|species:ncbi:215408">zebra fish</span>
Melk-like kinase plays a role in hematopoiesis in the zebra fish
###end article-title 97
###begin article-title 98
###xml 55 60 <span type="species:ncbi:10090">mouse</span>
Expression of Melk, a new protein kinase, during early mouse development
###end article-title 98
###begin article-title 99
###xml 41 47 <span type="species:ncbi:10090">murine</span>
Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers
###end article-title 99
###begin article-title 100
###xml 36 44 36 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xenopus </italic>
###xml 36 43 <span type="species:ncbi:8355">Xenopus</span>
Cellcycle regulation of pEg3, a new Xenopus protein kinase of the KIN1/PAR-1/MARK family
###end article-title 100
###begin article-title 101
Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation
###end article-title 101
###begin article-title 102
###xml 62 68 <span type="species:ncbi:10090">murine</span>
Phosphorylation of a novel zinc-finger-like protein, ZPR9, by murine protein serine/threonine kinase 38 (MPK38)
###end article-title 102
###begin title 103
Figures and Tables
###end title 103
###begin p 104
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 90 94 90 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 248 254 248 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 297 301 297 301 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 382 387 382 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 488 492 488 492 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 581 586 581 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 684 688 684 688 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 1025 1029 1025 1029 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 1029 1038 1029 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 1213 1217 1213 1217 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 1420 1424 1417 1421 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(g) </bold>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 1290 1295 <span type="species:ncbi:9606">human</span>
Expression and distribution of MELK in human normal tissues and breast cancer cell lines. (a) Expression of MELK in 12 breast cancer specimens (case number; 42, 102, 247, 252, 302, 473, 478, 502, 552, 646, 769 and 779) by semi-quantitative RT-PCR. GAPDH served as a quantitative internal control. (b) Multiple tissue Northern blot analysis demonstrated that an approximately 2.7 kb MELK transcript was detected in the testis, thymus and small intestine. PBL, peripheral blood leukocytes. (c) Breast cancer cell line Northern blot analysis revealed that approximately 2.4 to 2.7 kb MELK variants were specifically expressed in breast cancer cell lines, but not in normal vital organs. (d) Schematic representation of three variant transcripts identified by cDNA library screening (see Materials and methods). White boxes indicate a coding region and black boxes indicate a non-coding region. Black and grey triangles indicate initiation codons, and white triangles indicate stop codons. Exon numbers are shown above each box. (e) In vitro translation assay of each variant isolated from cDNA library screening. The number within parentheses represents the predicted molecular weight (kDa) of each variant protein. (f) Expression of MELK proteins in eight breast cancer cell lines as well as human mammary epithelial cells (HMECs) shown by western blot analysis with an anti-MELK antibody. beta-Actin served as a control. (g) Schematic representation of the V1, V2 and V3 forms of MELK. The shaded boxes indicate the catalytic domain (amino acids 11 to 263 of the V1 protein). The KA1 domain is the kinase-associated domain in the carboxy-terminal region.
###end p 104
###begin p 105
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
###xml 194 198 194 198 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 207 211 207 211 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 441 457 438 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2-microglobulin </italic>
###xml 462 465 456 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2MG</italic>
###xml 832 834 823 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 844 846 835 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 863 865 854 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 875 877 866 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 896 897 887 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1103 1108 1094 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MELK </italic>
Effect of knockdown of MELK by small-interfering RNA (siRNA) on cell viability and proliferation. Four psiH1 promoter-based siRNA constructs (si-#1, si-#2, si-#3 and si-#4) were introduced into (a) T47D and (b) MCF-7 cell lines. SC refers to scramble used as a control for siRNA experiments. Gene silencing was evaluated by semi-quantitative RT-PCR and western blot analyses at four and five days after neomycin selection, respectively. beta2-microglobulin (beta2MG) was used as a control for normalization of semi-quantitative RT-PCR, and beta-actin was used as a control in western blot analysis. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were performed to evaluate cell viability at 10 days after neomycin selection, and graphed after standardization using the scramble control (SC) as 1.0 (T47D, P = 0.0003, P = 0.0013; MCF-7, P = 0.0001, P = 0.0001; unpaired t-test). Colony formation assays were carried out three weeks after neomycin selection (see Materials and methods). Two siRNA constructs (si-#3 and -#4) showed significant knockdown effects against internal MELK expression and inhibited cell growth in both T47D (a) and MCF-7 (b) cell lines. Values represent the average from triplicate experiments. Error bars indicate standard deviation.
###end p 105
###begin p 106
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 61 65 61 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 286 290 286 290 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 309 311 309 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 438 440 438 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 484 488 481 485 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 518 519 515 516 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 630 632 627 629 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 643 644 640 641 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 906 910 903 907 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 950 952 947 949 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1068 1069 1065 1066 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 1106 1110 1103 1107 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 1198 1199 1195 1196 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 1321 1325 1318 1322 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 1378 1380 1375 1377 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1476 1478 1473 1475 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1904 1906 1901 1903 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 356 361 <span type="species:ncbi:9606">human</span>
###xml 1580 1586 <span type="species:ncbi:9986">rabbit</span>
Identification of Bcl-GL as an interacting protein for MELK. (a) Silver staining of SDS-PAGE gels that contained the pulled-down cell lysates. The enlarged area covering Bcl-G shows the differential interaction between it and wild-type MELK (WT-MELK) and kinase-dead MELK (D150A-MELK). (b) Expression of Bcl-GL in eight breast cancer cell lines as well as human mammary epithelial cells (HMECs) by western blot analysis with an anti-Bcl-GL antibody. beta-Actin was used as a control. (c) Interaction of MELK with Bcl-GL. Extracts from HeLa-cells transfected with HA (hemagglutinin)-tagged WT-MELK (HA-WT-MELK) or Flag-tagged Bcl-GL (Flag-Bcl-GL), or a combination of these, were harvested 36 hours after transfection. The cell lysates were immunoprecipitated with anti-Flag M2 antibody. Precipitated proteins were separated by SDS-PAGE and western blotting analysis was performed with an anti-HA antibody. (d) Direct interaction of the MELK and Bcl-GL proteins. The upper panel indicates the amount of input of WT-MELK and D150A-MELK. His-tagged WT-MELK bound to Bcl-GL, but His-tagged D150A-MELK did not. (e) Schematic representation of the amino- and carboxy-terminal deletion constructs of Bcl-GL. The C-1 and C-2 constructs have the BH2 domain deleted, and the C-3 construct has both the BH2 and BH3 domains deleted. (f) Determination of the WT-MELK binding regions of Bcl-GL by immunoprecipitation. The HA-tagged WT-MELK and various peptide sequences of Flag-tagged Bcl-GL (Figure 3e) were pulled down by immunoprecipitation with Flag-M2 antibody and then immunoblotted with rabbit anti-Flag antibody. The expression of HA-tagged WT-MELK in total cell lysates was confirmed by western blotting analysis. As a control, immunoprecipitation was performed from cells co-transfected with pCAGGSn3FC (Mock) and HA-tagged WT-MELK (HA-WT-MELK) through all steps. Arrowheads indicate expression of each Bcl-GL peptide.
###end p 106
###begin p 107
###xml 25 27 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 27 35 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 37 41 37 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 212 213 212 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 286 290 286 290 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 358 360 358 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 397 398 397 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 483 485 483 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 576 580 576 580 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 580 589 580 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 658 660 658 660 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 720 722 720 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 806 808 806 808 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
MELK phosphorylates Bcl-GL in vitro. (a) Immunoprecipitates were subjected to immune complex kinase assay with wild-type (WT)-MELK or kinase-dead (D150A)-MELK). The single arrowhead indicates phosphorylated Bcl-GL, and the double arrowhead points to an autophosphorylated MELK protein. (b) Phosphorylation of a bacterial glutathione S-transferase (GST) Bcl-GL fusion recombinant protein (GST-Bcl-GL) by His-tagged WT-MELK (WT). The single arrowhead indicates phosphorylated GST-Bcl-GL protein, and the double arrowhead indicates an autophosphorylated His-tagged MELK protein. (c) In vitro phosphorylation of various partial amino-terminal constructs of Bcl-GL (N-1, N-2, N-3 and N-4; see Figure 3e) and full-length Bcl-GL (FL) by MELK. The single arrowheads indicate phosphorylated immunoprecipitated Bcl-GL proteins, and the double arrowhead indicates an autophosphorylated MELK recombinant protein.
###end p 107
###begin p 108
###xml 55 56 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 166 168 166 168 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 179 180 179 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 251 255 251 255 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 287 289 287 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 366 370 366 370 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 500 502 500 502 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 640 642 638 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 647 649 645 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 668 669 666 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 677 681 675 679 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 893 897 891 895 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 1047 1049 1045 1047 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 1265 1267 1261 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
MELK involvement in the apoptosis cascade through Bcl-GL. HA (hemagglutinin)-tagged MELK (HA-wild-type (WT)-MELK or HA-kinase-dead (D150A)-MELK) and Flag-tagged Bcl-GL (Flag-Bcl-GL) expression vectors were co-transfected into COS7 cells for 24 hours. (a) The expression of MELK and Bcl-GL proteins in the co-transfected cells were examined by western blot analysis. (b) TUNEL assays after transfection with pCAGGSnHC (HA-Mock), pCAGGSn3FH (Flag-Mock), HA-tagged MELK (WT and D150A), Flag-tagged Bcl-GL expression vectors, and combinations of these. Apoptotic cells were measured by counting of TUNEL staining (means +/- standard deviation, n = 3; P = 0.0001; unpaired t-test). (c) Representative images of TUNEL assays. Cells were labeled with DAPI (4',6-diamidino-2-phenylindole) for counting of total cell number. Apoptotic cells with DNA strand breaks were labeled with green fluorescence. (d) FACS analysis of cells collected after transfection with pCAGGSnHC (HA-Mock), pCAGGSn3FH (Flag-Mock), HA-tagged MELK (WT and D150A), Flag-tagged Bcl-GL expression vectors, and combinations of these. Proportions of apoptotic cells are indicated as percentages of sub-G1 populations. Each value represents the average of three experiments (means +/- standard deviation, n = 3).
###end p 108

